Grünenthal recruits AstraZeneca exec as CCO

9 May 2017

German family-owned drugmaker Grünenthal has appointed Mark Fladrich to the position of chief commercial officer (CCO) responsible for the firm’s entire global commercial organization.

Currently Mr Fladrich is area vice president, Southern and Western Europe, at AstraZeneca (LSE: AZN), based in the UK. He will join Grünenthal effective September 1, 2017.

Mr Fladrich has almost 30 years of experience in the pharmaceutical industry, and more than 20 years at AstraZeneca. The 57 year old Australian by nationality brings a broad variety of expertise – from in-market knowledge to regional and global sales and marketing to Grünenthal. Key highlights include large country management roles in Germany as well as more recently in Australia and New Zealand with respectively over $1 billion of sales revenue in each country.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK